BACKGROUND: A number of studies have investigated the relationship between fibroblast growth factor receptor1 (FGFR1) gene copy number and survival in non-small cell lung cancer (NSCLC) patients. However, conclusions reported by different parties seem to be inconsistent, especially regarding the differences among different histopathologic subtypes. To derive a more precise estimate of the prognostic significance of FGFR1 gene copy number, we have reviewed published studies and carried out a meta-analysis. METHODS: The meta-analysis was conducted in accordance with PRISMA guidelines. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and an overall HR was calculated. RESULTS: We identified 6 eligible studies, all dealing with NSCLC. The global quality score ranged 32.5-80%, with a median of 53.33%. For FGFR1 amplification in three studies including differed according to histological type, the overall RR was 0.86 which 95% confidence interval (CI) was 0.75 to 0.99 and P value was 0.048. Combined HR for the six evaluable studies was 1.17 (95% CI: 0.95 to 1.43). In the subgroup of squamous cell lung cancer (SQCC), the combined HR was 1.24 (95% CI: 0.89 to 1.73). For the Asian populations' studies, the combined HR was 1.67 (95% CI: 1.1 to 2.52). CONCLUSIONS: FGFR1 amplification significantly was more frequent in SQCC. FGFR1 was not associated with poorer survival in patients with NSCLC. Furthermore studies will be needed in terms of survival implications.
BACKGROUND: A number of studies have investigated the relationship between fibroblast growth factor receptor1 (FGFR1) gene copy number and survival in non-small cell lung cancer (NSCLC) patients. However, conclusions reported by different parties seem to be inconsistent, especially regarding the differences among different histopathologic subtypes. To derive a more precise estimate of the prognostic significance of FGFR1 gene copy number, we have reviewed published studies and carried out a meta-analysis. METHODS: The meta-analysis was conducted in accordance with PRISMA guidelines. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and an overall HR was calculated. RESULTS: We identified 6 eligible studies, all dealing with NSCLC. The global quality score ranged 32.5-80%, with a median of 53.33%. For FGFR1 amplification in three studies including differed according to histological type, the overall RR was 0.86 which 95% confidence interval (CI) was 0.75 to 0.99 and P value was 0.048. Combined HR for the six evaluable studies was 1.17 (95% CI: 0.95 to 1.43). In the subgroup of squamous cell lung cancer (SQCC), the combined HR was 1.24 (95% CI: 0.89 to 1.73). For the Asian populations' studies, the combined HR was 1.67 (95% CI: 1.1 to 2.52). CONCLUSIONS:FGFR1 amplification significantly was more frequent in SQCC. FGFR1 was not associated with poorer survival in patients with NSCLC. Furthermore studies will be needed in terms of survival implications.
Authors: E Steels; M Paesmans; T Berghmans; F Branle; F Lemaitre; C Mascaux; A P Meert; F Vallot; J J Lafitte; J P Sculier Journal: Eur Respir J Date: 2001-10 Impact factor: 16.671
Authors: Anne M Schultheis; Marc Bos; Katja Schmitz; Lea Wilsberg; Elke Binot; Jürgen Wolf; Reinhard Büttner; Hans-Ulrich Schildhaus Journal: Mod Pathol Date: 2013-07-26 Impact factor: 7.842
Authors: Rebecca S Heist; Mari Mino-Kenudson; Lecia V Sequist; Swathi Tammireddy; Laura Morrissey; David C Christiani; Jeffrey A Engelman; A John Iafrate Journal: J Thorac Oncol Date: 2012-12 Impact factor: 15.609
Authors: Hye Ryun Kim; Dae Joon Kim; Dae Ryong Kang; Jin Gu Lee; Sun Min Lim; Chang Young Lee; Sun Young Rha; Mi Kyung Bae; Young Joo Lee; Se Hoon Kim; Sang-Jun Ha; Ross Andrew Soo; Kyung Young Chung; Joo Hang Kim; Ji Hyun Lee; Hyo Sup Shim; Byoung Chul Cho Journal: J Clin Oncol Date: 2012-11-26 Impact factor: 44.544
Authors: Vitor Sousa; Diana Reis; Maria Silva; Ana Maria Alarcão; Ana Filipa Ladeirinha; Maria João d'Aguiar; Teresa Ferreira; Sandra Caramujo-Balseiro; Lina Carvalho Journal: Virchows Arch Date: 2016-05-19 Impact factor: 4.064
Authors: Alberto Servetto; Rahul Kollipara; Luigi Formisano; Chang-Ching Lin; Kyung-Min Lee; Dhivya R Sudhan; Paula I Gonzalez-Ericsson; Sumanta Chatterjee; Angel Guerrero-Zotano; Saurabh Mendiratta; Hiroaki Akamatsu; Nicholas James; Roberto Bianco; Ariella B Hanker; Ralf Kittler; Carlos L Arteaga Journal: Clin Cancer Res Date: 2021-05-19 Impact factor: 12.531